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Featured Application: This study shows differences in the efficacy of hyaluronic acid (HA), au-
tologous conditioned serum (ACS) and bone marrow aspirate concentrate (BMAC) intra-articular
injections to improve pain and symptoms of knee OA up to one year after treatment. BMAC treat-
ment gives best results at 12 months and is effective also in the patients with more advanced knee
osteoarthritis (OA). The study results will be beneficial in making evidence-based orthopaedic
decisions on the method of OA treatment based on the levels of cartilage wear, as no clear guide-
lines have been provided regarding this issue.
Abstract: The aim of this study was to evaluate and compare the effectiveness of three different
intra-articular injective treatments: hyaluronic acid (HA), autologous conditioned serum (ACS) and
bone marrow aspirate concentrate (BMAC) for the treatment of knee osteoarthritis (OA). A Level III
retrospective comparative clinical study was performed on 505 consecutive patients treated with HA
(n = 171), ACS (n = 222) or BMAC (n = 112) for knee OA. The mean patient age was 52 ± 13 years;
54.5% were males. Collected data included patient demographics, symptoms, visual analogue scale
(VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and radiographic
classification of osteoarthritis grade using plain radiographs and advanced imaging. Clinical outcome
was assessed at 3 and 12 months post treatment. Significant improvement in VAS and WOMAC was
seen for all three treatments at the 3-month follow-up. At 12 months, VAS was improved in all three
treatment groups, yet only BMAC sustained the improved WOMAC even in patients with more
severe degenerative changes. This study shows that BMAC is more effective than HA and ACS in
the treatment of symptomatic knee OA, especially in the patients with more severe degenerative
changes.
Keywords: osteoarthritis; knee; hyaluronic acid; autologous conditioned serum; bone marrow
aspirate concentrate; clinical outcome
1. Introduction
Osteoarthritis (OA) is a multifactorial joint disease that can lead to pain, dysfunction
and a decreased quality of life [1]. It is the most common joint disorder, affecting millions
of people worldwide [2,3]; knee OA is one of the main reasons for physical disability [4].
Unfortunately, there is no disease-modifying medical intervention to prevent or cure
this disease. Therefore, the mainstay of treatment is focused on symptom relief. Many
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patients revert to total joint arthroplasty for definitive management of their OA; however,
this is not always a viable option, depending on patient age, surgical risk and medical
comorbidities [5]. A widely used conservative treatment measure is intra-articular injection
of corticosteroids [2]. Over the past two decades, the use of naturally derived preparations,
called orthobiologics, for various orthopedic conditions has become increasingly popular,
including for the management of knee OA. This includes the improvement or regeneration
of different musculoskeletal tissues by means of biomaterials (e.g., hyaluronic acid (HA)),
stem cells and growth factors (e.g., platelet-rich plasma (PRP)) [6,7].
However, neither intra-articular corticosteroids nor HA and PRP injectables have been
recommended for the management of knee OA in the guidelines published by the American
Academy of Orthopaedic Surgeons (AAOS) [5,8]. Cell products were not considered in
these guidelines.
Basic science studies have found that orthobiologics—unlike corticosteroids—have the
potential to improve the condition of the joint rather than just the symptom by modulating
inflammation and facilitating cartilage healing [9–14].
Some of the most frequently used types of orthobiologics include hyaluronic acid
(HA) as an important component of the intercellular matrix [15–17], platelet rich plasma
(PRP) [11,12,14,18,19] and autologous conditioned serum (ACS) [20,21], as well as cell
preparations from stem cell rich sources [22].
Cell products include cultivated mesenchymal stem cells (MSCs) [23], adipose de-
rived mesenchymal stem cells (AD MSC) [24], adipose derived stromal vascular fraction
(AD-SVF) [25] and bone marrow aspirate concentrate (BMAC) [26]. Different cell treat-
ments show a significant improvement in functional outcome and in tissue regeneration,
resulting in improved radiological outcome parameters [22,27,28]. Moreover, MSCs of-
fer the potential for cartilage regeneration owing to their effective immunomodulatory
properties and anti-inflammatory abilities [29]. There is growing evidence that PRP has
anti-inflammatory characteristics [30], whereas ACS has even superior immunomodulat-
ing capacity [20,21]. PRP treatment has been shown to decrease pain, but no significant
disease-altering properties have been consistently reported [5]. PRP augmentation has
also been shown as beneficial to accelerate and prolong the therapeutic effect of microfrac-
turation for the treatment of OA [31]. Hyaluronic acid injections are thought to work
by two separate mechanisms of action [15]. First, the viscosupplementation lubricates
damaged cartilage surfaces, allowing for less friction and inflammation and therefore less
joint pain and swelling. Secondly, HA acts as a nutrient for chondrocytes that may still be
able to heal when given a more favorable, nutrient-rich environment [15]. Clinical trials
have demonstrated its effectiveness for the management of knee OA and superiority to
corticosteroid injections when the duration of symptom relief is of concern 16,17].
The aim of this study was to evaluate the clinical effectiveness of three intra-articular
injections (HA, ACS and BMAC) in the treatment of symptomatic knee OA. There are
a few studies comparing various kinds of orthobiologics [21,32–34]. However, to our
knowledge, currently there are no studies simultaneously comparing the outcomes of HA,
ACS and BMAC intra-articular injection treatments for the management of knee OA. It was
hypothesized that the three treatments would result in symptom improvement, and that
BMAC would have the greatest effect on pain and dysfunction, followed by ACS and HA.
2. Materials and Methods
A retrospective clinical study was conducted between 2009 and 2018 on patients
with OA of the knee, graded according to Kellgren-Lawrence (KL) [35,36], treated either
with HA, ACS or BMAC via intra-articular injection. The treatment method was selected
according to the patient’s preferences regarding the procedure’s invasiveness and cost. In
clinical practice, it is generally more likely to start with less invasive and also less expensive
treatment in patients with a lower degree of degenerative changes. All three treatments
were performed by the first author. From a total of 644 potentially eligible cases, treated
with HA, ACS or BMAC during the defined period, 505 met the inclusion criteria: 171 in
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the HA group, 222 in the ACS group and 112 in the BMAC group (Figure 1, Table 1). The
study protocol was approved by the National Medical Ethics Committee (approval number
0120-286/2018-4).
Figure 1. Flowchart of the study showing the number of eligible patients, number of included patients and number of
included knees, reasons for exclusion and follow-up percentage at 3 and 12 months. HA = hyaluronic acid; ACS = autologous
conditioned serum; BMAC = bone marrow aspirate concentrate.
Table 1. Demographic data of the included cases.
Age Sex Laterality
Treatment









HA 51 ± 15 88 (52) 83 (48) 76 (44) 95 (56)
ACS 51 ± 13 121 (57) 101 (43) 109 (49) 113 (51)
BMAC 52 ± 10 66 (59) 46 (41) 52 (46) 60 (54)





p = 0.689 p = 0.469 p = 0.654
SD = standard deviation; N = number of cases; HA = hyaluronic acid; ACS = autologous conditioned plasma;
BMAC = bone marrow aspirate concentrate.
2.1. Inclusion and Exclusion Criteria
The inclusion criteria were as follows: (1) KL classification of knee OA grades I–III,
diagnosed on radiograph and MRI imaging; (2) pain in the knee joint (VAS ≥ 1); and
(3) the patient age between 18 and 80 years. The exclusion criteria were as follows: (1)
grade IV degenerative changes as determined by the KL classification, (2) if the grade of
arthritis could not be determined from the medical records, (3) inflammatory arthropathies
such as rheumatoid arthritis and connective tissue diseases, (4) the presence of another
source of significant pain or dysfunction affecting the ability to isolate symptoms of the
affected knee when evaluating the effectiveness of the treatment and (5) if the patients had
already received a similar type of injection or surgical intervention within 12 months prior
to treatment.
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2.2. Treatment Procedures
In the HA group, patients were treated with an intra-articular injection of 500–730
kDA sodium hyaluronate (Suplasyn, Mylan, Zurich, Switzerland). Patients received three
injections of 20 mg of this substance, in 2 mL of volume, at weekly intervals as suggested
by He et al. [17].
Patients treated with ACS (Orthokin, Orthogen, Dusseldorf, Germany) had 60 mL
of their own blood drawn from the antecubital fossa by an experienced nurse in sterile
conditions. The collecting system was then used to spin down and process the autologous
blood into ACS. It was then frozen and stored under −20 ◦C, according to manufacturer’s
instructions and quality standards employed by the institution conducting the study.
Patients received a total of six intra-articular injections every 3–4 days for 3 weeks as
suggested by manufacturer.
The BMAC group underwent bone marrow aspiration by the first author using a com-
mercially available procedure kit (Regen Extracell, RegenLab SA, Lousanne, Switzerland).
Patients were placed in supine position, the harvest site was prepared and draped in the
standard fashion and a total of 32 mL of bone marrow was aspirated from the anterior iliac
crest under general anesthesia. Using the aforementioned kit, aspirated bone marrow was
concentrated to 8 mL/application. A single intra-articular injection of 8 mL of BMAC was
performed on the same day as bone marrow aspiration.
All patients also received instructions for post-treatment rehabilitation including
exercises, daily and sports activities as recommended by AAOS guidelines for management
of OA.
2.3. Outcome Measures
Prior to intervention, demographic data (age, sex, laterality), plain radiographs and
magnetic resonance imaging (MRI) studies scans were collected for all cases. The grade of
OA was documented using the KL classification [35,36]. In addition, all patients assessed
their pain and symptom severity using the Visual Analogue Scale (VAS) and Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The VAS score was
used for general subjective estimation of pain, whereas the WOMAC is more specific for
pain associated with orthopaedic problems. After the treatment, patients were followed
for a minimum of 1 year. None of the patients had serious adverse events (e.g., infection,
allergic reaction, the need to have the knee drained or surgical irrigation and debridement).
After treatment, two patients treated with BMAC reported severe pain up to 7 days post
treatment. The VAS and WOMAC were repeated at 3 and 12 months following intervention.
Some patients were lost to follow-up which resulted in 145 HA cases (84%), 201 ACS cases
(90.5%) and 98 BMAC cases (87.5%) at 3 months; and 30 HA cases (17.5%), 50 ACS cases
(22.5%) and 25 BMAC cases (22.3%) at 12 months (Figure 1). The demographic data of
the included subjects is displayed in Table 1. The average patient age was 52 years (SD
13 years); 54% of cases were males and 46% females. Knee OA involved the right knee in
53% of cases and the left knee in 47%. There were no significant demographic differences
among the treatment groups.
2.4. Statistical Analysis
All results were checked for normality, and subsequently reported as mean and
standard deviation (SD). Statistical analysis was performed using SPSS (version 25, IBM
Corporation Armonk, New York, NY, USA). Continuous data are expressed as means with
standard deviation. Test of normality (Shapiro Wilks) was used for ANOVA in residuals to
verify the adherence to normality assumptions. One-way analysis of variance (ANOVA)
testing and Bonferroni post-hoc test were used to determine the differences between the
treatment groups. The Spearman’s rank test was used to determine the association of the
OA grade and patient age with VAS and WOMAC scores. A paired samples t-test was used
for within group analysis of treatment efficacy. Statistical significance was set at p < 0.05.
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3. Results
3.1. Baseline Characteristics of Treatment Groups
OA grade, VAS and WOMAC score for each of the three treatment groups prior to
intervention are displayed in Table 2. At baseline, there was a difference in OA severity and
symptoms; the highest OA grade, VAS and WOMAC scores were observed in the BMAC
group (2.6 ± 0.5, 5.2 ± 1.3 and 7.9 ± 2.2, respectively), and the lowest in the HA group (2.1
± 0.7, 3.9 ± 1.6 and 5.8 ± 1.9, respectively) (p < 0.001). Due to significant differences in
baseline values of VAS and WOMAC scores, score changes were used for comparison of
treatment efficacy among the treatment groups.
Table 2. Preintervention difference in grade of osteoarthritis, VAS and WOMAC scores between treatment groups.
Treatment Group HA ACS BMAC Significance
Mean (SD) Mean (SD) Mean (SD) p Value
OA grade 2.13 ± 0.74 2.35 ± 0.73 2.62 ± 0.54 † p = 0.007, ‡ p = 0.003,
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BMAC 0.39 † <0.001 0.26 0.788
Total 0.47 † <0.001 0. <0.001
OA = osteoarthritis; VAS = Visual Analogue Scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; HA = hyaluronic
acid; ACS = autologous cond tioned plasma; BMAC = b e marrow aspirate concentrate; † statistically significan correlation.
3.2. Follow-Up Outcomes
The changes in VAS and WOMAC scores in all three treatment groups at the 3- and
12-month follow-ups are presented in Figure 2. Significant improvement was observed in
all groups at 3 months in both scores; however, at 12 months, a significant improvement
as compared to baseline values persisted in the VAS score in he ACS group, and in both
the VAS and WOMAC scores in the BMAC group (Tables 4 and 5). Pain as significantly
mo e persistent i older patients a older patient age was associated wi h a high r VAS
(r = −0.21, p < 0.001) and WOMAC core (r = −0.13, p = 0.008) at the 3-month follow-up.
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Figure 2. Forest plot showing VAS and WOMAC scores in patients treated with three different treatment modalities.
Mean score values ± SEM are presented. Sample sizes of individual groups are presented in Figure 1. OA = osteoarthritis;
VAS = Visual Analogue Scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index. HA = hyaluronic
acid; ACS = autologous conditioned serum; BMAC = bone marrow aspirate concentrate.
Table 4. Change in VAS score 3 and 12 months after the treatment with HA, ACS and BMAC.









HA 4.3 ± 1.2 (171) 2.2 ± 1.4 (145) 2.9 ± 3.0 (30) † p < 0.001, ‡ p = 0.017, p = 0.164
ACS 4.5 ± 1.3 (222) 1.9 ± 1.0 (201) 2.7 ± 2.8 (50) † p < 0.001, ‡ p < 0.001, p < 0.001
BMAC 4.7 ± 1.5 (112) 1.8 ± 0.8 (98) 3.0 ± 0.8 (25) † p < 0.001, ‡ p = 0.003, p = 0.003
Total 4.5 ± 1.3 (505) 1.6 ± 1.15 (444) 2.9 ± 2.7 (105) † p < 0.001, ‡ p < 0.001, p < 0.001
VAS = Visual Analogue Scale; HA = hyaluronic acid; ACS = autologous conditioned serum; BMAC = bone marrow aspirate concentrate;
statistically significant improvement between † 0 and 3 months, ‡ 0–12 months, 3–12 months.
Table 5. Change in WOMAC score 3 and 12 months after the treatment with HA, ACS and BMAC.









HA 6.25 ± 1.78 (171) 3.24 ± 2.01 (145) 5.32 ± 6.0 (30) † p < 0.001, ‡ p = 0.278,
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= . 55
ACS 6.64 ± 2.08 (222) 2.38 ± 1.27 (201) 5.57 ± 4.65 (50) † p < 0.001, ‡ p = 0.143,
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OA grade 2.13 ± 0.74 2.35 ± 0.73 2.62 ± 0.54 † p = 0. 7, ‡ p = 0.003, ⫩ p < 0.001 
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BMAC 7.68 ± 2.54 (112) 2.84 ± 2.32 (98) 5.12 ± 3.00 (25) † p < 0.001, ‡ p = 0.005,
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Total 6.86 ± 2.16 (505) 2.74 ± 1.82 (444) 5.39 ± 4.70 (105) † p < 0.001, ‡ p = 0.003,
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3.2. Follow-Up Outcomes 
The changes in VAS and WOMAC scores in all three treatment groups at the 3- and 
12-m nth follow-ups are presented in Figure 2. Significant improvement was observed in 
all groups at 3 months in both scores; however, at 12 months, a significant improvement 
as compared to baseline values persisted in the VAS score in the ACS group, and in both 
. 01
WOMAC Western Ontario and McMaster Universities Oste arthritis Index; HA = hyaluronic acid; ACS autologous conditioned serum;
BMAC = bone marrow aspirate concentrate; statistically significant improvement between † 0 and 3 months, ‡ 0–12 months, 3–12 months.
3.3. Association of Pain Score Changes with OA Grade
The association of pain score changes with OA grade in different treatment groups
was analysed. Table 6 sh ws the correlation between the OA r and the changes in the
VAS and WOM C scores at 3 and 12 months in response to treatment. Negative r valu s
mean that better improv ment i achieved in patients with a higher OA grade, and posit e
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values mean that a better improvement is achieved in patients with lower OA grades. In
general, better short-term (at 3 months) results are observed in patients with higher grades
of OA, and better long-term results are observed in patients with lower grades of OA.
The patients from the three treatment groups with OA grade I and II had improvement in
pain and function at both 3 and 12 months after treatment; the short-term improvement
achieved in patients with grade III changes was decreased at 12 months (Figure 3); negative
values of the presented score changes mean decrease of pain.
Table 6. Correlation between grade of OA and change in VAS and WOMAC score over the follow-up period.
Spearman Correlation Coefficient
between OA Grade & VAS Change
r (p Value)
Spearman Correlation Coefficient
between OA Grade & WOMAC Change
r (p Value)







HA −0.20 (0.015) † 0.50 (0.005) † −0.42 (<0.001) † 0.68 (<0.001) †
ACS −0.36 (<0.001) † 0.26 (0.069) −0.44 (<0.001) † 0.17 (0.056)
BMAC −0.27 (0.006) † −0.06 (0.78) 0.06 (0.592) 0.16 (0.459)
Total −0.33 (<0.001) † 0.28 (0.004) † −0.39 (0.001) † 0.34 (<0.001) †
OA = osteoarthritis; VAS = Visual Analogue Scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index;
HA = hyaluronic acid; ACS = autologous conditioned serum; BMAC = bone marrow aspirate concentrate; mo = month; f/u = follow-up; †
statistically significant correlation.
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Figure 3. Forest plot showing VAS and WOMAC score changes in patients with different OA 
grades for the overall study cohort. Mean values of score change ± SEM are presented. OA = osteo-
arthritis; VAS = Visual Analogue Scale; WOMAC = Western Ontario and McMaster Universities 
Osteoarthritis Index; mo = months; f/u = follow-up. 
Figure 4 shows the changes in VAS and WOMAC scores according to the grade of 
OA in different treatment groups to illustrate associations given in Table 6. The improve-
ment in pain scores at 3 months decreased significantly at 12 months in all three treatment 
groups. In the HA group, an increase in the VAS and WOMAC scores at 12 months was 
observed in patients with grade III OA. In patients with grade III OA treated with ACS, 
pain scores were not significantly different from baseline values. In the BMAC group, a 
Figure 3. Forest plot showing VAS and WOMAC score changes in patients with different OA grades
for the overall study cohort. Mean values of score change ± SEM are presented. OA = osteoarthritis;
VAS = Visual Analogue Scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis
Index; mo = months; f/u = follow-up.
Figure 4 shows the changes in VAS and WOMAC scores according to the grade of OA
in different treatment groups to illustrate associations given in Table 6. The improvement in
pain scores at 3 months decreased significantly at 12 months in all three treatment groups.
In the HA group, an increase in the VAS and WOMAC scores at 12 months was observed
in patients with grade III OA. In patients with grade III OA treated with ACS, pain scores
were not significantly different from baseline values. In the BMAC group, a significant
decrease in pain scores was sustained at the 12-month follow-up, even in cases with OA
grade III (Figure 4).
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Figure 4. Forest plot showing VAS and WOMAC score changes in patients with different OA grades for the patient
groups treated with separate treatment methods. Mean values of score change ± SEM are presented. OA = osteoarthritis;
VAS = Visual Analogue Scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index. HA = hyaluronic
acid; ACS = autologous conditioned serum; BMAC = bone marrow aspirate concentrate.
4. Discussion
The aim of this study was to compare the efficacy of HA, ACS and BMAC in the
treatment of symptomatic knee OA. The most important findings were that all three
treatment methods resulted in an improvement in the VAS and WOMAC scores at the
3-month follow-up. However, at 12 months, the WOMAC scores remained improved only
in patients treated with BMAC. In addition, BMAC was most effective in the patients with
more severe (KL grade III) degenerative changes.
The lack of sustained effect of HA treatment is consistent with previous reports in
the literature. A meta-analysis of 76 trials comparing various types of HA injections to
other treatment options for OA concluded that HA had a positive effect on pain associated
with weightbearing function, and the positive effect was most pronounced 5 to 13 weeks
post injection [37]. The current AAOS guidelines cannot recommend HA for symptomatic
knee OA; although some meta-analyses have shown improvement in the WOMAC score,
the number of points with which patients assessed their improvement did not meet the
minimal clinically important improvement thresholds [8]. In this study, the treatment
with ACS showed an improvement in the VAS but not in the WOMAC score at 1 year
after treatment, which is somewhat different from previous studies. Yang et al., looking at
the efficacy of ACS in the treatment of symptomatic knee OA in a double-blind placebo-
controlled trial, found an improvement in the Knee Injury and Osteoarthritis Outcome
Score (KOOS) and in the symptom and sport subscores [38]. Although there appeared to
be a trend towards improvement in other three subscores as compared to placebo, this did
not reach statistical significance. Similar to the present study, they did not find a significant
difference in the WOMAC score at 12-month post treatment [38]. Baltzer et al. compared
ACS to HA and normal saline [20] and found that all three treatment groups showed
symptom reduction. In line with the present study, the symptom reduction was better with
ACS and HA, but they found no difference in improvement between HA and normal saline.
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They noted, however, that HA injection had a significantly higher complication rate than
ACS and normal saline [20].
BMAC has been found superior to HA and ASC in the present study, showing an effect
of treatment even at a 12-month follow-up; it was most effective in patients with higher
grade knee OA. A potential explanation may be that the pluripotent stem cells present in
BMAC are able to promote chondrogenesis and cartilage regeneration [23,26,32,34,39]. In
addition, these cells can secrete certain growth factors resulting in an anti-inflammatory
and immunomodulating effect on the knee, which may slow down or even prevent OA
progression [40]. Consistent with this, a meta-analysis by Jeyaraman et al. showed a statis-
tically significant improvement after MSC (derived either from bone marrow or adipose
tissue) transplantation in all functional outcome measures such as VAS for pain, WOMAC,
Lysholm, Knee Injury and Osteoarthritis Outcome Score (KOOS) and radiological outcome
parameters such as Whole-Organ Magnetic Resonance Imaging Score (WORMS) at differ-
ent time intervals with their corresponding controls. The study showed an improvement in
OA symptoms with a bone marrow derived cultured stem cell injection; the VAS score was
found improved even at 2 years post treatment. However, the authors pointed out that
there were no studies comparing the effect of BMAC and culture expanded bone marrow
derived mesenchymal stem cells (BM-MSCs) [31].
Similar to the present study, other studies have indicated that the effectiveness of OA
treatment is directly related to the severity of the disease [26,27]. Centeno et al. looked at
BMAC with and without an adipose graft for knee OA and found that both were equally
effective, but the magnitude of symptom improvement was dependent on the grade of
degenerative changes also in their study [26]. Kim et al. looked at the effect of BMAC
with adipose tissue injection on OA symptoms [27]. They found an improvement in the
International Knee Documentation Committee (IKDC), Short Form 36 (SF-36), Lysholm and
KOOS scores. Although all patients had symptom improvement with treatment, the effect
was much less in the patients with grade IV KL changes, when compared to the patients
with grade I–III changes. The same authors further reported mid-term follow-up results
of OA patients treated with BMAC [41]. They found that the VAS scores five years after
treatment were significantly lower than the preoperative scores; however, the improvement
in VAS scores was significantly greater in patients with KL Grade I or II than in those with
KL Grade III or IV.
Lastly, the present study has shown an effect of age on the outcome of treatment,
which is seen in some [42] but not in other of the aforementioned studies [5,43]. This can be
partly explained by older patients generally having more advanced degenerative changes,
as well as by the reduced number of stem cells available and their proliferative capacity
with increased age [44–46].
Study Limitations and Strengths
As a retrospective study, the present study does have some limitations. Treatment was
not randomized, patients and providers were not blinded to the treatment provided and no
placebo or saline group was used. The number of cases included in each treatment group
was different. Initially, a relatively large number of patients were present in each group;
however, a significant number of patients were lost to follow-up between 3 and 12 months
post treatment. There were baseline differences between the groups in the grade of OA,
VAS and WOMAC. This is largely due to the retrospective nature of the study as in these
patients presenting with milder degenerative changes in the clinical setting, it is more likely
to start with the least invasive and also the least expensive treatment [15,47]. Lastly, the
efficacy of the treatment could be affected by other factors such as at the frequency/number
of treatment visits. The BMAC group had only one single visit, whereas three visits were
needed in the HA group, and six were needed in the ACS group. The number of visits
and time spent with the treating physician might have an additional placebo effect on
the perceived efficacy of treatment, although this has not been confirmed by previous
research [48].
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The strengths of the study are that this is the first study to report comparison of three
different orthobiologic treatments. All patients were treated by the same surgeon with
the same technique and underwent the same rehabilitation protocol, therefore minimizing
variability of treatment procedure among involved individuals.
This study highlights the potential of orthobiologics in the treatment of knee OA.
In the future, prospective trials with large patient numbers and longer follow-ups are
needed to further elucidate the duration of their efficacy. For this, patients should be
additionally followed with MRI imaging tests to get objective data as well as patient
subjective assessments of treatment outcomes.
5. Conclusions
This study shows that HA, ACS and BMAC intra-articular injections improve pain
and symptoms of knee OA up to three months after treatment. However, BMAC is more
effective than HA and ACS as it sustains symptom improvement for at least 12 months
post treatment. In addition, BMAC is the most effective in the patients with more advanced
knee OA.
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